SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Childs who wrote (2605)11/18/1997 6:33:00 PM
From: DR. BOND  Read Replies (1) | Respond to of 23519
 
I disagree....Given the limited amount of time, I think Lee Wilson did a great job getting VVUS's message across. Also, Podolski summed it up well, THE MARKET IS HUGE AND MANY PLAYERS WILL GET THEIR FAIR SHARE, AS WELL AS VIAGRA WILL EXPAND MUSE"S MARKET SHARE BY BRINGING MORE MEN INTO UROLOGIST OFFICES FOR THERAPY! Padma-Nathan was well balanced and unbiased (unusual for him) and Hemant Shah came across as being unqualified to answer questions in this area.

Any other opinions are welcome!

UK IMMINENT!

DB



To: Steve Childs who wrote (2605)11/18/1997 6:33:00 PM
From: mc  Respond to of 23519
 
Steve, the important thing about MUSE is the delivery system.



To: Steve Childs who wrote (2605)11/18/1997 6:42:00 PM
From: Gene Voss  Respond to of 23519
 
<is Vivus's drug generic>
Yes but patents protect transurethral delivery.Oral phentolamine is not protected.

GV


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News